ABAL
Abaloparatide
A synthetic 34-amino-acid analogue of parathyroid hormone-related protein, residues 1 to 34, with eight substitutions. It binds the same PTH1 receptor as teriparatide, and the published work describes it as favouring a different conformational state of that receptor — the structural distinction between the two compounds.
Abaloparatide has 19 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 3,959 planned or enrolled participants across the 17 studies that published a figure. An FDA-approved product contains Abaloparatide — TYMLOS (NDA208743). 372 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Abaloparatide; the registry search is fuzzy, so every match is re-checked. None of this says whether Abaloparatide works or is safe.
FDA status
Approved
Human studies
19
Furthest phase
Phase 4
Papers, 10 yr
372
Readership
563
monthly average, Feb–Jul 2026
Tracking since 2026-08-02 · About this data
What has actually been tested in humans
An approved product exists
19
Registered human studies
Phase 4
Furthest phase reached
3,959
Planned or enrolled participants, across 17 studies that published a figure
Approved
FDA-approved product — TYMLOS
25 loose registry matches were checked and 19 confirmed — 6 named something else and were discarded. We count a study only when Abaloparatide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Abaloparatide is, and what it has been studied for
Abaloparatide is classified by ChEMBL as a protein, and appears in trial registrations under BA-058 and BA058. Its FDA substance identifier is AVK0I6HY2U.
Across 19 registered trials, it has been studied in Osteoporosis, Osteoporosis, Postmenopausal, Postmenopausal Osteoporosis and Osteoporosis Localized to Spine. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Radius Health, Inc. and Hospital for Special Surgery, New York among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Abaloparatide reached Phase 4 across 19 registered trials.
An FDA-approved product contains Abaloparatide. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying Abaloparatide?
Papers published each year that name Abaloparatide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 33 | 0 | Yes |
| 2018 | 35 | 2 | Yes |
| 2019 | 44 | 4 | Yes |
| 2020 | 41 | 4 | Yes |
| 2021 | 39 | 3 | Yes |
| 2022 | 42 | 1 | Yes |
| 2023 | 49 | 1 | Yes |
| 2024 | 48 | 1 | Yes |
| 2025 | 56 | 0 | Yes |
| 2026 | 36 | 1 | No |
372 papers and 17 registered trials between 2017 and 2026. A paper counts when “Abaloparatide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Abaloparatide
372 indexed papers name Abaloparatide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial
- The clinician's guide to prevention and treatment of osteoporosis
- Osteoporosis: A Review
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
- Osteoporosis
- Abaloparatide
- Osteoporosis in Older Adults
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians
Collected 2026-08-02from PubMed, phrase-matched on “Abaloparatide” in title and abstract. Run the same search.
About Abaloparatide
A synthetic 34-amino-acid analogue of parathyroid hormone-related protein, residues 1 to 34, with eight substitutions. It binds the same PTH1 receptor as teriparatide, and the published work describes it as favouring a different conformational state of that receptor — the structural distinction between the two compounds.
- Also known as
- BA-058 · BIM-44058
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.